Taysha Gene Therapies, Inc.
TSHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,006 | $599 | $326 | $377 |
| - Cash | $297 | $313 | $117 | $139 |
| + Debt | $17 | $60 | $61 | $63 |
| Enterprise Value | $725 | $346 | $271 | $301 |
| Revenue | $0 | $2 | $2 | $2 |
| % Growth | -100% | -13.7% | 13.8% | – |
| Gross Profit | -$0 | $2 | $2 | $2 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | -$32 | -$27 | -$21 | -$18 |
| % Margin | – | -1,338.8% | -922.1% | -912.9% |
| Net Income | -$33 | -$27 | -$22 | -$19 |
| % Margin | – | -1,353.6% | -935.2% | -929% |
| EPS Diluted | -0.093 | -0.09 | -0.08 | -0.092 |
| % Growth | -2.7% | -12.9% | 12.9% | – |
| Operating Cash Flow | -$24 | -$20 | -$22 | -$18 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$24 | -$20 | -$22 | -$18 |